Dr. Marzia Del Re works as an Assistant Professor in the Clinical Pharmacology and Pharmacogenetics Unit at the University of Pisa (Italy). Her research program is focused on the 1) diagnosis of adverse drug reactions by pharmacogenetic analysis of germline DNA and 2) monitoring of acquired resistance to targeted therapies using circulating nucleic acids released from tumors in plasma.

Dr. Del Re received her Pharm.D. degree in 2009 and became a Specialist in Clinical Biochemistry in 2014 at the University of Pisa. She obtained a Master’s degree in "Clinical trials in Oncology, Hematology and Internal Medicine" in 2015 and a Ph.D. title in Clinical Pathophysiology in 2018 at the University of Pisa.

Dr. Del Re received the Merit Awards from the American Society of Clinical Oncology (2011 and 2013) for her studies on DPYD variants and adverse drug reactions by fluoropyrimidines. Dr. Del Re received the Umberto Veronesi Foundation Fellowship (2012) for a project on pharmacogenetics of tamoxifen. Dr. Del Re was the recipient of a special award from the Italian Society of Pharmacology for her contribution to research in pharmacogenetics (2014) and the special award "SIF-Farmindustria for Pharmacological Research" (2016). In 2018, Dr. Del Re was awarded by the Italian Association of Medical Oncology (AIOM) for her research on circulating tumor DNA in lung cancer and in 2020 received the ESMO travel grant for the research “Ki67 expression and CDK4/6i activity: an emerging role for PIK3CA mutations in metastatic breast cancer patients”. In 2015, 2016, 2018 and 2019 Dr. Del Re worked for a total of 9 months at the Erasmus Medical Center, Rotterdam (Netherlands) as a Visiting Scientist, on projects revolving around drug resistance in prostate and lung cancer. In particular, she worked on exosomes isolation from plasma and RNA extraction, optimized the ddPCR assay and performed expression analyses on a large series of plasma samples. In 2017, Dr. Del Re worked at the NCI/NIH (Bethesda, USA) as a Visiting Scientist, on in vitro CRPC models.

From November 2022, Dr. Del Re works as a Visiting Professor at the Center for Thoracic Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai Hospital, working on liquid biopsy in lung cancer; and in August 2023, Dr. Del Re joined the Early Drug Development Unit at the Memorial Sloan Kettering Cancer Center (New York).